<DOC>
	<DOC>NCT00320359</DOC>
	<brief_summary>Evaluation of intravenous Topotecan + Cisplatin as a potential new standard of care in 1st line Small Cell Lung Cancer</brief_summary>
	<brief_title>Topotecan Plus Cisplatin Versus Etoposide Plus Cisplatin In 1st Line Extensive Disease Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Evaluable extensive small cell lung cancer, extensive disease. Eastern Cooperative Oncology Group (ECOG) performance status &lt; 2. Life expectancy &gt; 3 months. Fit to receive any of the treatments. No prior chemotherapy. Written informed consent. Extensive disease treatable with radiotherapy. Past or current history of other malignant disease. Prior chemotherapy. Pregnancy, lactating or lack of effective contraception. Concurrent severe medical problems other than small cell lung cancer. Patients with central nervous system metastases receiving more than 12 mg /day dexamethasone or equivalent to control symptoms.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>First-line Cisplatin</keyword>
	<keyword>Small Cell Lung Cancer</keyword>
	<keyword>topotecan</keyword>
	<keyword>etoposide</keyword>
	<keyword>Extensive Disease</keyword>
</DOC>